[New agents for the prevention of venous thromboembolism].
Harenberg
J
J
Klinische Pharmakologie Mannheim, Ruprecht-Karls-Universität Heidelberg, Maybachstrasse 14, 68169 Mannheim. job.harenberg@medma.uni-heidelberg.de
Nitschmann
S
S
D001562:Benzimidazoles / Q000008:administration & dosage*; D000069604:Dabigatran; D017984:Enoxaparin / Q000008:administration & dosage*; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D000069552:Rivaroxaban; D013876:Thiophenes / Q000008:administration & dosage*; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000188:drug therapy* / Q000517:prevention & control*
D001562:Benzimidazoles; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D009025:Morpholines; D011725:Pyridines; D013876:Thiophenes; D000069552:Rivaroxaban; D000069604:Dabigatran